1. The Alteration of HDL in Patients with AMI Inhibited Angiogenesis by Blocking ERK1/2 Activation
- Author
-
Wei Zhang, Zhe Li, Wen-Qi Han, Qun-Rang Wang, Hao-Yu Wu, Xin-Hong Liu, Kun Xing, Gong Cheng, and Feng-Jun Chang
- Subjects
Pharmacology ,Article Subject ,MAP Kinase Signaling System ,Human Umbilical Vein Endothelial Cells ,Myocardial Infarction ,Humans ,Pharmacology (medical) ,General Medicine ,Phosphorylation ,Lipoproteins, HDL ,Cardiology and Cardiovascular Medicine - Abstract
Objective. High-density lipoprotein (HDL) was found vasoprotective, but numbers of patients with acute myocardial infarction (AMI) have normal or even high levels of pathological HDL (pHDL). So, we investigate the mechanism of pHDL in AMI patients on angiogenesis. Methods. HDL with normal levels from healthy subjects (nHDL, control group, n = 20 ) and patients with AMI (pHDL, experimental groups, n = 30 ) were obtained by super high speed centrifugation. Then, effects of HDL on proliferation, migration, angiogenesis, and expression of ERK1/2 and its phosphorylation in human umbilical vein endothelial cells (HUVEC) with or without PD98059 (inhibitor of ERK1/2) preincubation were detected. Results. Compared with the control group (nHDL), HDL from the experimental group (pHDL) significantly inhibited the phosphorylation of ERK1/2, proliferation, migration, and angiogenesis of HUVEC ( P < 0.05 ), while these effects of HDL could substantially be blocked by preincubation of PD98059 ( P < 0.05 ). Conclusion. HDL in AMI patients affects angiogenesis by inhibiting ERK1/2 activation free from HDL levels.
- Published
- 2022
- Full Text
- View/download PDF